Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;71(3):128-33.

Bortezomib-induced polyneuropathy

A J J Rampen  1 , J L M Jongen, I van Heuvel, M Scheltens-de Boer, P Sonneveld, M J van den Bent
Affiliations
  • PMID: 23712808
Free article

Bortezomib-induced polyneuropathy

A J J Rampen et al. Neth J Med. 2013 Apr.
Free article

Abstract

Background: Peripheral neuropathy is a frequent side effect of bortezomib chemotherapy. Relatively little is known about the clinical characteristics of this neuropathy, especially with respect to pain. Our aim was to describe the clinical characteristics and course of bortezomib-induced polyneuropathy.

Methods: This is a retrospective cohort study of 39 patients diagnosed with bortezomib-induced polyneuropathy.

Results: Pain is the most prominent symptom and 14 of 39 patients suffered from severe pain. More than 50% of our patients used analgesics due to moderate or severe pain. We found no correlation between severity of symptoms of bortezomib-induced polyneuropathy and cumulative dose or dose intensity of bortezomib. Nerve conduction studies did not correlate well with symptom severity. Dose reduction or discontinuation of treatment reduced severity in most cases.

Conclusion: Painful polyneuropathy is a frequent, dose-limiting side effect of bortezomib with a relatively good prognosis. Careful neurological monitoring of symptoms and timely dose adjustment is important.

PubMed Disclaimer

LinkOut - more resources